Abstract
Lafora disease (LD) is a devastating childhood epilepsy caused by intracellular, aberrant glycogen aggregates called Lafora bodies (LBs) in the brain and other tissues. Herein, Brewer et al. generated a first-in-class antibody-enzyme fusion, VAL-0417, that degrades LBs in vitro and in vivo in a pre-clinical model, showing promise as a LD drug.
Original language | English |
---|---|
Pages (from-to) | 689-705.e6 |
Journal | Cell Metabolism |
Volume | 30 |
Issue number | 4 |
DOIs | |
State | Published - Oct 1 2019 |
Bibliographical note
Publisher Copyright:© 2019 Elsevier Inc.
Keywords
- Lafora bodies
- Lafora disease
- amylase
- antibody-based drug
- antibody-enzyme fusion
- enzyme therapy
- epilepsy
- glycogen
- glycogen storage disease
- metabolomics
ASJC Scopus subject areas
- Physiology
- Molecular Biology
- Cell Biology